Praxis Precision Medicines (PRAX)

• Market cap: $1.43B
• 1 day: 5.05%
• 5 days: 8.52%
• 1 month: 3.85%
• 3 months: 24.40%
• 6 months: 90.78%
• Year to date: 266.12%
• 1 year: 323.00%
• 5 years: -81.65%
• 10 years: -81.65%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.

Employees: 82

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

133% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 15

20% more call options, than puts

Call options by funds: $24M | Put options by funds: $20M

18% more funds holding

Funds holding: 113 [Q2] → 133 (+20) [Q3]

2% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 43

0% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 5 (+0) [Q3]

2.55% less ownership

Funds ownership: 108.77% [Q2] → 106.22% (-2.55%) [Q3]

55% less capital invested

Capital invested by funds: $2.42B [Q2] → $1.09B (-$1.33B) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $120 57% upside
• Avg. target: $145 89% upside
• High target: $163 113% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 43% 1-year accuracy 71 / 167 met price target	57% upside $120	Buy Reiterated	12 Dec 2024
Needham Ami Fadia 37% 1-year accuracy 57 / 154 met price target	97% upside $151	Buy Reiterated	7 Nov 2024
Oppenheimer Francois Brisebois 43% 1-year accuracy 15 / 35 met price target	113% upside $163	Outperform Maintained	31 Oct 2024